Fluvoxamine-d4 is intended for use as an internal standard for the quantification of fluvoxamine by GC- or LC-MS. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI).1 It selectively inhibits reuptake of serotonin over norepinephrine reuptake in rat hypothalamic synaptosomes (Kis = 6.2 and 1,100 nM, respectively). Fluvoxamine (10 mg/kg) reduces immobility time in the forced swim test in mice, an effect that can be blocked by the sigma-1 (σ1) receptor antagonist BD 1047 .2 It also reduces marble-burying behavior in the marble-burying test in mice when administered at a dose of 45 mg/kg, indicating anxiolytic- or reduced obsessive compulsive-like behaviors.3 Formulations containing fluvoxamine have been used in the treatment of obsessive compulsive disorder and social anxiety disorder.
1.Johnson, A.M.An overview of the animal pharmacology of paroxetineActa Psychiatr. Scand.80(Suppl. 350)14-20(1989) 2.Sugimoto, Y., Tagawa, N., Kobayashi, Y., et al.Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetineEur. J. Pharmacol.696(1-3)96-100(2012) 3.Hayashi, A., Yamashita, N., Baba, J., et al.Effects of co-administered fluvoxamine and diazepam, ethyl loflazepate or imipramine on marble-burying behavior in miceOyo Yakuri57(5-6)103-108(1999)